tiprankstipranks
Trending News
More News >

Tourmaline Bio initiated with a Buy at Chardan

Chardan analyst Daniil Gataulin initiated coverage of Tourmaline Bio (TRML) with a Buy rating and $70 price target The firm cites the potential of the company’s lead asset, the anti-IL6 antibody pacibekitug, in thyroid eye disease and atherosclerotic cardiovascular disease for the Buy rating. It also sees additional upside potential in abdominal aortic aneurysm.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1